Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

59.50
+1.382.37%
Post-market: 59.550.0500+0.08%19:59 EDT
Volume:2.45M
Turnover:149.15M
Market Cap:5.75B
PE:-12.50
High:62.54
Open:59.72
Low:58.89
Close:58.12
52wk High:78.48
52wk Low:44.12
Shares:96.69M
Float Shares:93.17M
Volume Ratio:1.25
T/O Rate:2.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7595
EPS(LYR):-6.4700
ROE:-26.09%
ROA:-14.20%
PB:3.29
PE(LYR):-9.20

Loading ...

Week's Best: Spacex is Changing Market Indexes. ETF Investors, Take Note.

Dow Jones
·
Jun 27

Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts

TIPRANKS
·
Jun 24

Thanks to SpaceX, Index Funds Won't Track Each Other as Closely. Here's One Pro's Advice. -- Barrons.com

Dow Jones
·
Jun 23

Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts

TIPRANKS
·
Jun 13

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)

TIPRANKS
·
Jun 11

Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next

Simply Wall St.
·
Jun 07

Shareholders Approve New Incentive Plan and Governance Measures

TIPRANKS
·
Jun 05

CRISPR Therapeutics shareholders approve 2026 stock option and incentive plan at annual meeting

Reuters
·
Jun 05

Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Jun 04

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift

Simply Wall St.
·
May 29

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 28

Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial

TIPRANKS
·
May 23

Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)

TIPRANKS
·
May 14

A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest

Simply Wall St.
·
May 12

Vertex Pharmaceuticals announces Casgevy reimbursement agreement

TIPRANKS
·
May 07

Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
May 06

Editas Medicine Announces First Quarter 2026 Results and Business Updates

GlobeNewswire
·
May 05

CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83

TIPRANKS
·
May 05

CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated

TIPRANKS
·
May 05